Stock VIVIMEDLAB VIVIMED LABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vivimed Labs Limited

Equities

VIVIMEDLAB

INE526G01021

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:25 2023-07-31 am EDT 		5-day change 1st Jan Change
4.95 INR -1.00% Intraday chart for Vivimed Labs Limited -.--% -.--%
Feb. 26 Vivimed Labs CFO Resigns MT
Feb. 24 Vivimed Labs Limited Announces Resignation of Ramakanta Tripathy as Chief Financial Officer CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 5,872 1,919 601.1 1,335 1,202 547.2
Enterprise Value (EV) 1 13,121 10,521 9,523 4,527 4,719 4,320
P/E ratio 7.62 x 3.49 x -0.55 x -1.86 x -1.78 x -0.17 x
Yield 0.56% - - - - -
Capitalization / Revenue 0.49 x 0.14 x 0.06 x 0.15 x 0.5 x 0.29 x
EV / Revenue 1.1 x 0.79 x 0.89 x 0.52 x 1.98 x 2.3 x
EV / EBITDA 6.32 x 5.56 x 48.7 x 9.31 x -69.7 x -2.32 x
EV / FCF -8.33 x 7.92 x 24.7 x 2.29 x -35.1 x 6.39 x
FCF Yield -12% 12.6% 4.04% 43.6% -2.85% 15.7%
Price to Book 0.65 x 0.31 x 0.12 x 0.31 x 0.33 x 1.39 x
Nbr of stocks (in thousands) 82,524 82,524 82,914 82,914 82,914 82,914
Reference price 2 71.15 23.25 7.250 16.10 14.50 6.600
Announcement Date 9/12/18 9/7/19 12/8/20 1/13/23 3/3/23 10/20/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 11,953 13,381 10,671 8,713 2,386 1,881
EBITDA 1 2,075 1,891 195.4 486.4 -67.72 -1,859
EBIT 1 1,510 1,223 -474 -68.51 -250.5 -2,050
Operating Margin 12.64% 9.14% -4.44% -0.79% -10.5% -109.03%
Earnings before Tax (EBT) 1 857.1 660.4 -1,095 -698.6 -648.3 -3,306
Net income 1 779.4 573.6 -1,091 -718.9 -676.5 -3,285
Net margin 6.52% 4.29% -10.23% -8.25% -28.36% -174.69%
EPS 2 9.332 6.670 -13.16 -8.670 -8.159 -39.62
Free Cash Flow 1 -1,575 1,329 385.1 1,973 -134.3 676.3
FCF margin -13.18% 9.93% 3.61% 22.65% -5.63% 35.96%
FCF Conversion (EBITDA) - 70.29% 197.12% 405.69% - -
FCF Conversion (Net income) - 231.7% - - - -
Dividend per Share 2 0.4000 - - - - -
Announcement Date 9/12/18 9/7/19 12/8/20 1/13/23 3/3/23 10/20/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 7,250 8,602 8,922 3,192 3,517 3,773
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.494 x 4.549 x 45.67 x 6.562 x -51.93 x -2.029 x
Free Cash Flow 1 -1,575 1,329 385 1,973 -134 676
ROE (net income / shareholders' equity) 7.71% 5.26% -12.3% -11.4% -17% -163%
ROA (Net income/ Total Assets) 4.24% 3.24% -1.31% -0.24% -1.23% -11.4%
Assets 1 18,394 17,723 83,587 293,772 55,202 28,896
Book Value Per Share 2 109.0 75.00 61.40 52.10 43.90 4.750
Cash Flow per Share 2 12.00 11.50 6.090 0.7800 0.8700 0.4500
Capex 1 1,635 891 1,128 - 164 49.7
Capex / Sales 13.68% 6.66% 10.57% - 6.88% 2.64%
Announcement Date 9/12/18 9/7/19 12/8/20 1/13/23 3/3/23 10/20/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
VIVIMED LABS LIMITED Stock Vivimed Labs Limited
-.--% 4.92M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VIVIMEDLAB Stock
  4. Financials Vivimed Labs Limited